Restricted accessResearch articleFirst published online 2012-01
The New Self-Inactivating Lentiviral Vector for Thalassemia Gene Therapy Combining Two HPFH Activating Elements Corrects Human Thalassemic Hematopoietic Stem Cells
To address how low titer, variable expression, and gene silencing affect gene therapy vectors for hemoglobinopathies, in a previous study we successfully used the HPFH (hereditary persistence of fetal hemoglobin)-2 enhancer in a series of oncoretroviral vectors. On the basis of these data, we generated a novel insulated self-inactivating (SIN) lentiviral vector, termed GGHI, carrying the Aγ-globin gene with the −117 HPFH point mutation and the HPFH-2 enhancer and exhibiting a pancellular pattern of Aγ-globin gene expression in MEL-585 clones. To assess the eventual clinical feasibility of this vector, GGHI was tested on CD34+ hematopoietic stem cells from nonmobilized peripheral blood or bone marrow from 20 patients with β-thalassemia. Our results show that GGHI increased the production of γ-globin by 32.9% as measured by high-performance liquid chromatography (p=0.001), with a mean vector copy number per cell of 1.1 and a mean transduction efficiency of 40.3%. Transduced populations also exhibited a lower rate of apoptosis and resulted in improvement of erythropoiesis with a higher percentage of orthochromatic erythroblasts. This is the first report of a locus control region (LCR)-free SIN insulated lentiviral vector that can be used to efficiently produce the anticipated therapeutic levels of γ-globin protein in the erythroid progeny of primary human thalassemic hematopoietic stem cells in vitro.
Get full access to this article
View all access options for this article.
References
1.
AnagnouN.P., Perez-StableC., GelinasR.et al.1995. Sequences located 3′ to the breakpoint of the hereditary persistence of fetal hemoglobin-3 deletion exhibit enhancer activity and can modify the developmental expression of the human fetal A γ-globin gene in transgenic mice. J. Biol. Chem., 270:10256–10263.
2.
ArumugamP.I., ScholesJ., PerelmanN.et al.2007. Improved human β-globin expression from self-inactivating lentiviral vectors carrying the chicken hypersensitive site-4 (cHS4) insulator element. Mol. Ther., 15:1863–1871.
3.
ArumugamP.I., UrbinatiF., VeluC.S.et al.2009. The 3′ region of the chicken hypersensitive site-4 insulator has properties similar to its core and is required for full insulator activity. PLoS One, 4:e6995.
4.
BlouinM.J., BeaucheminH., WrightA.et al.2000. Genetic correction of sickle cell disease: Insights using transgenic mouse models. Nat. Med., 6:177–182.
5.
BunnF.H.2001. Human hemoglobins: Sickle hemoglobin and other mutants. Molecular Basis of Blood Diseases, 2ndStamatoyannopoulosG., MajerusP.W., PelmutterR.M., VarmusH.Saunders: Philadelphia, 183–226.
6.
Cavazzana-CalvoM., PayenE., NegreO.et al.2010. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature, 467:318–323.
7.
CharacheS., CleggJ.B., WeatherallD.J.1976. The negro variety of hereditary persistence of fetal haemoglobin is a mild form of thalassaemia. Br. J. Haematol., 34:527–534.
8.
ChungJ.H., BellA.C., FelsenfeldG.1997. Characterization of the chicken β-globin insulator. Proc. Natl. Acad. Sci. U.S.A., 94:575–580.
9.
CollinsF.S., MetherallJ.E., YamakawaM.et al.1985. A point mutation in the A gamma-globin gene promoter in Greek hereditary persistence of fetal haemoglobin. Nature, 313:325–326.
10.
DespratR., BouhassiraE.E.2009. Gene specificity of suppression of transgene-mediated insertional transcriptional activation by the chicken HS4 insulator. PLoS One, 4:e5956.
11.
DullT., ZuffereyR., KellyM.et al.1998. A third-generation lentivirus vector with a conditional packaging system. J. Virol., 72:8463–8471.
12.
FeingoldE.A., PennyL.A., NienhuisA.W., ForgetB.G.1999. An olfactory receptor gene is located in the extended human β-globin gene cluster and is expressed in erythroid cells. Genomics, 61:15–23.
13.
FessasP., StamatoyannopoulosG.1964. Hereditary persistence of fetal hemoglobin in Greece: A study and a comparison. Blood, 24:223–240.
14.
FragkosM., AnagnouN.P., TubbJ., EmeryD.2005. Use of hereditary persistence of fetal hemoglobin 2 enhancer to increase the expression of oncoretrovirus vectors for human γ-globin. Gene Ther., 12:1591–1600.
15.
GazouliM., KatsantoniE.Z., KosteasT., AnagnouN.P.2009. Persistent fetal γ-globin expression in adult transgenic mice following deletion of two silencer elements located 3′ to the human Aγ-globin gene. Mol. Med., 15:415–424.
16.
Hacein-Bey-AbinaS., Von KalleC., SchmidtM.et al.2003. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science, 302:415–419.
17.
HanawaH., HargroveP.W., KepesS.et al.2004. Extended β-globin locus control region elements promote consistent therapeutic expression of a γ-globin lentiviral vector in murine β-thalassemia. Blood, 104:2281–2290.
18.
HanawaH., YamamotoM., ZhaoH.et al.2009. Optimized lentiviral vector design improves titer and transgene expression of vectors containing the chicken β-globin locus HS4 insulator element. Mol. Ther., 17:667–674.
19.
HargroveP.W., KepesS., HanawaH.et al.2008. Globin lentiviral vector insertions can perturb the expression of endogenous genes in β-thalassemic hematopoietic cells. Mol. Ther., 16:525–533.
20.
ImrenS., PayenE., WestermanK.A.et al.2002. Permanent and panerythroid correction of murine β thalassemia by multiple lentiviral integration in hematopoietic stem cells. Proc. Natl. Acad. Sci. U.S.A., 99:14380–14385.
21.
KatsantoniE.Z., LangeveldA., WaiA.W.K.et al.2003. Persistent γ-globin expression in adult transgenic mice is mediated by HPFH-2, HPFH-3, and HPFH-6 breakpoint sequences. Blood, 102:3412–3419.
22.
KattamisC., Metaxotou-MavromatiA., LadisV.et al.1982. The clinical phenotype of β and δβ thalassemias in Greece. Eur. J. Pediatr., 139:135–138.
23.
KosteasT., PalenaA., AnagnouN.P.1997. Molecular cloning of the breakpoints of the hereditary persistence of fetal hemoglobin type-6 (HPFH-6) deletion and sequence analysis of the novel juxtaposed region from the 3′ end of the β-globin gene cluster. Hum. Genet., 100:441–445.
24.
LebensburgerJ., PersonsD.A.2008. Progress toward safe and effective gene therapy for β-thalassemia and sickle cell disease. Curr. Opin. Drug Discov. Dev., 11:225–232.
25.
LisowskiL., SadelainM.2007. Locus control region elements HS1 and HS4 enhance the therapeutic efficacy of globin gene transfer in β-thalassemic mice. Blood, 110:4175–4178.
26.
MathiasL.A., FisherT.C., ZengL.et al.2000. Ineffective erythropoiesis in β-thalassemia major is due to apoptosis at the polychromatophilic normoblast stage. Exp. Hematol., 28:1343–1353.
27.
MiccioA., CesariR., LottiF.et al.2008. In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of β-thalassemia. Proc. Natl. Acad. Sci. U.S.A., 105:10547–10552.
28.
MigliaccioG., Di PietroR., Di GiacomoV.et al.2002. In vitro mass production of human erythroid cells from the blood of normal donors and of thalassemic patients. Blood Cells Mol. Dis., 28:169–180.
29.
OrkinS.H., NathanD.1998. The thalassemias. Nathan and Oski's Hematology of Infancy and Childhood, 5thOrkinS.H., NathanD.Saunders: Philadelphia, 811–886.
30.
PapanikolaouE., AnagnouN.P.2010. Major challenges for gene therapy of thalassemia and sickle cell disease. Curr. Gene Ther., 10:404–412.
31.
PersonsD.A., AllayE.R., SabatinoD.E.et al.2001. Functional requirements for phenotypic correction of murine β-thalassemia: Implications for human gene therapy. Blood, 97:3275–3282.
32.
PersonsD.A., HargroveP.W., AllayE.R.et al.2003. The degree of phenotypic correction of murine β-thalassemia intermedia following lentiviral-mediated transfer of a human γ-globin gene is influenced by chromosomal position effects and vector copy number. Blood, 101:2175–2183.
33.
PerumbetiA., HigashimotoT., UrbinatiF.et al.2009. A novel human gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: Critical determinants for successful correction. Blood, 114:1174–1185.
34.
PestinaT.I., HargroveP.W., JayD.et al.2009. Correction of murine sickle cell disease using gamma-globin lentiviral vectors to mediate high-level expression of fetal hemoglobin. Mol. Ther., 17:245–252.
35.
PuthenveetilG., ScholesJ., CarbonellD.et al.2004. Successful correction of the human β-thalassemia major phenotype using a lentiviral vector. Blood, 104:3445–3453.
36.
RivellaS., MayC., ChadburnA.et al.2003. A novel murine model for Cooley anemia and its rescue by lentiviral-mediated human β-globin gene transfer. Blood, 101:2932–2939.
37.
RoselliE.A., MezzadraR., FrittoliM.C.et al.2010. Correction of β-thalassemia major by gene transfer in haematopoietic progenitors of pediatric patients. EMBO Mol. Med., 2:1–14.
38.
Santoni de SioF.R., NaldiniL.2009. Short-term culture of human CD34+ cells for lentiviral gene transfer. Methods Mol. Biol., 506:59–70.
39.
Santoni de SioF.R., CascioP., ZingaleA.et al.2006. Proteasome activity restricts lentiviral gene transfer into hematopoietic stem cells and is down-regulated by cytokines that enhance transduction. Blood, 107:4257–4265.
40.
StamatoyannopoulosG., FessasP., PapayannopoulouT.1969. F-thalassemia: A study of thirty-one families with simple heterozygotes and combinations of F-thalassemia with A2-thalassemia. Am. J. Med., 47:194–208.
41.
TateV.E., WoodW.G., WeatherallD.J.1986. The British form of hereditary persistence of fetal hemoglobin results from a single base mutation adjacent to an S1 hypersensitive site 5′ of the Aγ globin gene. Blood, 68:1389–1393.
42.
TuanD., FeingoldE., NewmanM.et al.1983. Different 3′ end points of deletions causing delta beta-thalassemia and hereditary persistence of fetal hemoglobin: Implications for the control of gamma-globin gene expression in man. Proc. Natl. Acad. Sci. U.S.A., 80:6937–6941.
43.
WeatherallD.J.1998. Pathophysiology of thalassemia. Baillieres Clin. Haematol., 11:127–146.
44.
WeatherallD.J.2001. The thalassemias. Molecular Basis of Blood Diseases, 3rdStamatoyannopoulosG., NienhuisA.W., MajerusP.W., VarmusH.Saunders: Philadelphia, 185–229.
45.
WheelerJ.T., KrevansJ.R.1961. The homozygous state of persistent fetal hemoglobin and the interaction of persistent fetal hemoglobin with thalassemia. Bull. Johns Hopkins Hosp., 109:217–233.
46.
WilberA., HargroveP.W., KimY.S.et al.2011. Therapeutic levels of fetal hemoglobin in erythroid progeny of β-thalassemic CD34+ cells following lentiviral vector-mediated gene transfer. Blood, 117:2817–2826.
47.
ZuffereyR., DullT., MandelR.J.et al.1998. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol., 72:9873–9880.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
